Vol. 4 No. 11 (2024)
Reimbursement Reviews

Pembrolizumab (Keytruda)

Published November 21, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (100 mg/4 mL vial solution for IV infusion).
  • Indication: Pembrolizumab in combination with gemcitabine-based chemotherapy is indicated for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.